COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE IN THE TREATMENT OF PATIENTS WITH HER2+EARLY BREAST CANCER (EBC) AND RESIDUAL DISEASE AFTER NEOADJUVANT TREATMENT IN COLOMBIA

A. Taborda, D. Murillo,P. A. Taborda, D. Ballen, A. Russi,A. Robles

VALUE IN HEALTH（2022）

引用 0|浏览0

暂无评分

摘要

To estimate, from the health system perspective, the cost-effectiveness of the use of trastuzumab emtasine (T-DM1), compared with trastuzumab, for the adjuvant treatment of adult patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy in Colombia.

查看译文

关键词

trastuzumab emtansine,neoadjuvant treatment,breast cancer,cost-effectiveness

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要